Low dose BCG as adjuvant therapy for superficial bladder cancer and literature review

ANZ Journal of Surgery

Volumn 74, Issue 7, 2004, Pages 569-572

  Cheng, C W ^a   Ng, M T ^a   Chan, S Y ^a   Sun, W H ^a  

^a ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

Author keywords

Bacillus Calmette Guerin; Bladder cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CHILL; CLINICAL ARTICLE; CYSTITIS; CYSTOSCOPY; DISEASE COURSE; DRUG TOLERABILITY; DYSURIA; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; MAINTENANCE THERAPY; MALE; PAIN; POLLAKISURIA; RETROSPECTIVE STUDY; REVIEW; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; URINARY URGENCY; URINE CYTOLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; URINARY BLADDER NEOPLASMS;

EID: 3442890006     PISSN: 14451433     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2004.02941.x     Document Type: Review

References (18)

1. Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 1995; 13: 1404-8.
2. Pagano F, Bassi P, Milani C, Meneghini A, Maruzzi D, Garbeglio A. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J. Urol. 1991; 146: 32-5.
3. Lamm DL, Reichert DF, Harris SC, Lucio RM. Immunotherapy of murine transitional cell carcinoma. J. Urol. 1982; 128: 1104-8.
4. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha2b plus low dose bacillus calmette-guerin is effective in patients with superficial bladder cancer in whom bacillus calmette-guerin alone previously failed. J. Urol. 2001; 166: 1300-5.
5. Morales A, Nickel JC, Wilson JWL. Dose-response of bacillus Calmette-Guerin in the treatment of superficial bladder cancer. J. Urol. 1992; 147: 1256-8.
6. Mack D, Frick J. Low-dose bacilli Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada. Br. J. Urol. 1995; 75: 185-7.
7. Mack D, Frick J. Five-year results of a phase II study with low-dose bacilli Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology 1995; 45: 958-61.
8. Takashi M, Wakai K, Ohno Y, Murase T, Miyake K. Evaluation of a low-dose intravesical bacillus Calmette-Guerin (Tokyo strain) therapy for superficial bladder cancer. Int. Urol. Nephrol. 1995; 27: 723-33.
9. Pagano F, Bassi P, Piazza N, Abatangelo G, Drago Ferrante GL, Milani C. Improving the efficacy of BCG immunotherapy by dose reduction. Eur. Urol. 1995; 27: 19-22.
10. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, Grade 3 bladder cancer therapy. J. Urol. 1996; 156: 1602-5.
11. Lebret T, Gaudez F, Herve JM, Barre P, Lugagne PM, Botto H. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Eur. Urol. 1998; 34: 67-72.
12. Yalcinkaya F, Kamis L, Ozteke O, Gunlusoy B, Yigitbasi O, Unal S. Prospective randomized comparison of intravesical BCG therapy with standard dose versus low doses in superficial bladder cancer. Int. Urol. Nephrol. 1998; 30: 41-4.
13. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J. Urol. 2000; 163: 68-71.
14. Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J. Urol. 2000; 163: 63-7.
15. Martinez-Pineiro JA, Flores S, Isoma E et al. Long-term follow-up of a randomized prospective trial comparing a standard 81mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. Br. J. Urol. 2002; 89: 671-80.
16. Lamm DL, Stogdill VD, Stogdill BJ et al. Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J. Urol. 1986; 135: 272-4.
17. Lamm DL, van der Meijden PM, Morales A et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 1992; 147: 56-600.
18. Dalbagni G, Herr HW. Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol. Clin. North Am. 2000; 27: 137-46.